Prognostic and Therapeutic Implications of ADAM17 and TRIM24in Epithelial Ovarian Carcinomas

Le résumé fourni par la source

Ovarian cancer is a lethal gynecological malignancy as it represents the 5th leading cause of death among women. So, it is an important issue for novel biomarkers identification for its early diagnosis and improving the efficacy of ovarian cancer treatment. A disintegrin and , metalloproteinase- (ADAM) -17 is revealed the essential component in regulation cellular processes from proliferation till migration. Tripartite Motif-Containing 24 (TRIM24) is a co-regulator of transcription process. Clinical utility of those biomarkers remains unclear in determination prognosis and identification of ovarian carcinoma. So We aimed for evaluating prognostic value of ADAM17 and TRIM24 expression with determine their correlation to clinicopathologic features in ovarian carcinoma patients. Methods: A total of biopsy specimens were retrospectively diagnosed as ovarian carcinoma then evaluation for all cases by immunohistochemical staining with ADAM17 and TRIM24. Follow up for 5 years for detection disease recurrence and survival. Results: ADAM117 and TRIM24 expression augmented in EOC and they were related to advanced clinicopathological categories that connected to inferior prognosis of cases. Conclusion: ADAM17 and TRIM24 are prognostic markers for ovarian epithelial carcinoma that can stratify patients into low and at a high risk of disease progression and then can receive intense dose of chemotherapeutic agents and novel target agents.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.